PeptiSystems Secures Growth Investment to Accelerate Commercial Expansion
December 17, 2025
PeptiSystems has secured a growth equity investment from Rubicon Healthcare Partners to accelerate its commercial expansion and international growth. The investment marks a major milestone for the company as it continues to scale its advanced manufacturing solutions for peptide- and oligonucleotide-based therapeutics.
The funding will enable PeptiSystems to further strengthen its organization, expand globally, and support biopharmaceutical companies and CDMOs as they transition from development into GMP-scale manufacturing. The company has seen growing commercial momentum, underpinned by increasing demand for efficient, scalable, and sustainable production technologies.
Rubicon Healthcare Partners, a Nordic growth investor focused on life science tools, services, and enabling technologies, will become the largest shareholder following the transaction. In addition to capital, Rubicon brings deep sector expertise and an international network to support PeptiSystems’ next phase of growth.
About PeptiSystems
PeptiSystems is a life science company, based in Uppsala, Sweden, focused on advancing manufacturing technologies for peptide and oligonucleotide therapeutics. The company develops modular synthesis platforms designed to improve process efficiency, scalability, and control across development and production environments. PeptiSystems supports pharmaceutical companies and manufacturing partners in addressing the growing need for reliable, next-generation therapeutic production.
Learn more here.